The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Workshop of the Carolinas 2024 | Prefibrotic myelofibrosis: considerations for diagnosing and managing this entity
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the differences between prefibrotic myelofibrosis (MF), essential thrombocythemia (ET) and overt primary myelofibrosis (overt PMF), and highlights the distinguishable characteristics clinicians should use to diagnose these diseases. Dr Bose also highlights approaches to managing these diseases and further emphasizes the value of early intervention, with agents such as ruxolitinib and interferon, to delay disease progression. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support: Incyte, BMS, CTI (Sobi), Morphosys, Karyopharm, Sumitomo, Ajax, Disc, Ionis, Geron, Janssen, Cogent, Blueprint, Kartos, Telios.; Honoraria/consulting fees: Incyte, BMS, CTI (Sobi), GSK, Abbvie, Morphosys, Pharma Essentia, Sumitomo, Karyopharm, Ionis, Disc, Geron, Morphic, Jubilant, Ono, Novartis, Blueprint, Cogent.
